PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC

Abroad (travel likely)RecruitingPHASE2

Conditions

Hepato Cellular Carcinoma (HCC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

West China Hospital, Chengdu, Sichuan, China
Contact: Study coordinator (Yiwen Qiu, M.D.) · qyw@wchscu.edu.cn · +8613281003787

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab

Hepato Cellular Carcinoma (HCC)

Abroad (travel likely)RecruitingPHASE2

Bologna, Italy

SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin

Hepato Cellular Carcinoma (HCC) · Hand Foot Skin Syndrome

Abroad (travel likely)RecruitingPHASE2

Taipei, Taiwan

A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma

Hepato Cellular Carcinoma (HCC)

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma

Hepato Cellular Carcinoma (HCC)

Abroad (travel likely)RecruitingPHASE2

Shanghai, China